You searched for: ovarierespons (Danska - Engelska)

ohss på grund af overdreven ovarierespons kan undgås ved at seponere behandlingen med hcg.
ohss due to excessive ovarian response can be avoided by withholding hcg administration.

afhængigt af ovarierespons kan følgende foranstaltninger træffes for at nedsætte risikoen for ohss:
depending on the ovarian response, the following measurements can be considered to reduce ohss:

35 forhøjet ovarierespons til gonadotropinbehandling fører sjælden til ohss hvis ikke hcg administreres for at starte ovulation.
excessive ovarian response to gonadotrophin treatment seldom gives rise to ohss unless hcg is administered to trigger ovulation.

hvis deres læge ikke ser nogen ovarierespons efter 3 ugers behandling, skal man opgive den cyklus.
if your doctor does not observe a response of your ovaries after 3 weeks of treatment, that cycle should be abandoned.

omhyggelig monitorering af østradiolniveau og ovarierespons ved hjælp af ultralyd anbefales for alle patienter før og under stimulationsbehandling.
careful monitoring of estradiol levels and ovarian response, based on ultrasound is recommended prior to and during stimulation therapy, for all patients.

tidlig ohss opstår normalt indenfor 10 dage efter hcg administration og kan være forbundet med for højt ovarierespons på gonadotropin stimulation.
early ohss usually occurs within 10 days after hcg administration and may be associated with an excessive ovarian response to gonadotropin stimulation.

kvinder med kendte risikofaktorer for højt ovarierespons kan være særligt tilbøjelige til at udvikle ohss under eller efter behandling med fertavid.
women with known risk factors for a high ovarian response may be especially prone to the development of ohss during or following treatment with fertavid.

sikker og effektiv brug af pergoveris hos kvinder kræver overvågning af ovarierespons via ultralyd alene eller helst i kombination med regelmæssig måling af serumøstradiol.
in women, safe and effective use of pergoveris calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis.

sikker og effektiv brug af gonal- f hos kvinder kræver overvågning af ovarierespons via ultralyd alene eller helst i kombination med regelmæssig måling af serumøstradiol.
in women, safe and effective use of gonal-f calls for monitoring of ovarian response with ultrasound, alone or preferably in combination with measurement of serum oestradiol levels, on a regular basis.

hvis der ingen ovarierespons er, forhøjes den daglige dosis gradvist, indtil follikelvæksten og/ eller østradiol niveauerne indikerer et tilstrækkeligt farmakodynamisk respons.
if there is no ovarian response, the daily dose is then gradually increased until follicle growth and/ or plasma oestradiol levels indicate an adequate pharmacodynamic response.